Email updates

Keep up to date with the latest news and content from BMC Psychiatry and BioMed Central.

Open Access Correction

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Paul D Carey1*, Bavanisha Vythilingum1, Soraya Seedat1, Jacqueline E Muller1, Michael van Ameringen2 and Dan J Stein1

Author Affiliations

1 MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa

2 Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada

For all author emails, please log on.

BMC Psychiatry 2005, 5:44  doi:10.1186/1471-244X-5-44

Published: 30 November 2005

First paragraph (this article has no abstract)

The comment in the introduction of our article [1] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [2].